6130.Two

6130.TWO has a liquidity position characterized by a current ratio of 3.09, indicating a strong ability to meet short-term obligations with its current assets. The company holds cash and equivalents of 187,585,000 TWD, which is a significant portion of its total assets of 877,781,000 TWD. However, the company's operating cash flow is negative at -44,153,000 TWD, and its free cash flow is also negative at -117,469,000 TWD.

In terms of profitability, 6130.TWO reported a net income of -76,310,000 TWD, indicating a loss for the period. The return on equity is -13.99%, and the return on assets is -8.69%, both of which are below the industry median for pharmaceutical companies. The company's gross profit of 46,454,000 TWD is relatively low compared to its revenue of 154,736,000 TWD, suggesting challenges in maintaining profit margins.

The company's revenue is not segmented by geographic regions or product lines in the provided data, making it difficult to assess the concentration of revenue sources. However, the lack of detailed segment data implies that the company may not have a diversified revenue base, which could pose a risk if a particular market or product line underperforms.

Looking at the growth trajectory, 6130.TWO has reported a negative operating income of -84,840,000 TWD, indicating a decline in operational performance. The company's capital expenditure of -67,010,000 TWD suggests a reduction in investment in long-term assets, which could affect future growth potential. The analyst estimates for the last actual EPS and revenue are 2.88 TWD and 223,536,000 TWD, respectively, which may indicate a need for the company to improve its financial performance to meet these expectations.

The risk assessment for 6130.TWO indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.33 suggests a relatively low level of leverage, which is favorable from a risk perspective. However, the negative net income and operating income highlight the need for the company to address its profitability issues to maintain financial stability.

Recent events and filings do not show any significant changes or developments that would impact the company's financial position or strategic direction. The company's financial performance and risk profile suggest that it may need to implement cost-saving measures or explore new revenue streams to improve its financial health.